Clinical trials: Premenopausal Breast Cancer
Improve Sexual Health, Improve Vulvovaginal Health
A Study to Prevent and Improve Sexual Health Concerns for People With Breast Cancer
Researchers are doing this study to look at whether sexual health counselling and using non-hormonal moisturizer at the start of ovarian suppression may be able to prevent or reduce side effects such as vaginal dryness and sexual…
- Trial name
- NCT05910294
- Testing
- questionnaires, moisturizers
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Premenopausal Breast Cancer, Hormone Receptor-positive Breast Cancer
Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients
MORE-T trial is designed to investigate the effect of Tamoxifen 40mg (vs. Tamoxifen 20mg) for 2wks in presurgical setting. The greater reduction in Ki-67 might be observed in Tamoxifen 40mg arm compared to the Tamoxifen 20mg arm.
- Trial name
- MORE-T (NCT04997941)
- Testing
- Tamoxifen Oral Product, Assessment of Ki-67, Surgery
- Where
- South Korea
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Breast Cancer
Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex
The purpose of this study is to determine the efficacy and tolerance of the association of two drugs already marketed and used to treat your disease: Arimidex® 1 Mg per day per os and Zoladex® 3,6 Mg in injections under cutaneous…
- Trial name
- NCT00235937
- Testing
- Anastrozole and goserelin
- Where
- 7 sites in France
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Breast Cancer
Zoladex® 10.8 BC RWS
This is a multi-center, retrospective-prospective, observational, active-control, non-inferiority, real world study using hospital medical record data, with objectives to evaluate E2 suppressive effect of Zoladex® 10.8 mg is…
- Trial name
- NCT05184257
- Where
- 16 sites in China
- Volunteers
- 1,176 people
- Sponsor
- AstraZeneca
Breast Cancer
Adjuvant AI Combined With Zoladex
The present study is a randomized open-label -phase III study that aims to compare the efficacy of Zoladex® combined with Aromidex® for 3-2 years after SERMs (tamoxifen and Fareston®) as an adjuvant therapy for 2-3 years with the…
- Trial name
- NCT01352091
- Testing
- Zoladex+AI, TAM
- Where
- China
- Volunteers
- 670 people
- Sponsor
- Fudan University
Breast Cancer
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer.
- Trial name
- NCT00014222
- Testing
- epoetin alfa, filgrastim, cyclophosphamide
- Where
- 78 sites in United States, Canada
- Volunteers
- 2,104 people
- Sponsor
- NCIC Clinical Trials Group
Breast Atypical Ductal Hyperplasia, Breast Ductal Carcinoma In Situ
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
This phase III trial studies how well metformin hydrochloride works compared to placebo in preventing breast cancer in patients with atypical hyperplasia or in situ breast cancer.
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Trial name
- NCT01905046
- Testing
- metformin hydrochloride
- Where
- 27 sites in United States
- Volunteers
- 86 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer
This study will determine if hormone receptor positive premenopausal metastatic breast cancer patients who undergo removal of the ovaries in mid-luteal versus mid-follicular phase have a longer survival.
- Trial name
- NCT00293540
- Testing
- oophorectomy, Tamoxifen
- Where
- 21 sites in United States, Bangladesh and 8 more
- Volunteers
- 249 people
- Sponsor
- International Breast Cancer Research Foundation
Metastatic Breast Cancer
A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC
Despite recent advances for the treatment of post-menopausal hormone receptor-positive BC, in the last decade there was no major improvement of hormonal therapy specifically for premenopausal metastatic breast cancer.
- Trial name
- NCT02592746
- Testing
- Palbociclib, Exemestane, Leuprolide Acetate
- Where
- 2 sites in South Korea
- Volunteers
- 182 people
- Sponsor
- Samsung Medical Center
Breast Cancer
Raloxifene in Preventing Breast Cancer in Premenopausal Women
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of raloxifene may be an effective way to prevent breast cancer in premenopausal women.
- Trial name
- NCT00019500
- Testing
- raloxifene, evaluation of cancer risk factors
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Precancerous Condition
Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer
RATIONALE: Ground flaxseed may prevent breast cancer in premenopausal women at increased risk of developing primary breast cancer.
- Trial name
- NCT00794989
- Testing
- Ground Flaxseed, No Intervention
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
brca1 Mutation Carrier, brca2 Mutation Carrier
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
RATIONALE: Cholecalciferol may prevent breast cancer in premenopausal women. PURPOSE: This randomized phase II trial is studying how well cholecalciferol works in preventing breast cancer in premenopausal women.
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
- Trial name
- NCT01097278
- Testing
- cholecalciferol
- Where
- 360 sites in United States
- Volunteers
- 208 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer, Breast Cancer and Pregnancy
The Immune System's Response to Young Women's Breast Cancer
This study plans to learn more about the immune system's response to breast cancer in young women.
- Trial name
- NCT01503190
- Where
- 5 sites in United States
- Volunteers
- 800 people
- Sponsor
- University of Colorado, Denver
Breast Cancer
Vitamin D and Mammographic Breast Density
There is some evidence that vitamin D could be used to reduce breast cancer risk. Randomized controlled trials would provide definitive evidence about this effect.
- Trial name
- EVIDENSE (NCT01747720)
- Testing
- Vitamin D3
- Where
- Canada
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- CHU de Quebec-Universite Laval
HER2 Negative Breast Cancer
Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
This is a Phase II, two-arm, single center, patient preference study designed to evaluate the impact of omitting adjuvant chemotherapy in moderate to high-anatomical risk, low-genomic risk (men or premenopausal women T2-3N0 and…
- Trial name
- SELECT (NCT06953882)
- Testing
- Ribociclib 400mg, Letrozole 2.5mg, Anastrazole 1mg
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Yale University
Breast Cancer
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
The purpose of this study is to determine the safety and tolerability of the combination of two drugs (letrozole and leuprolide) in women who have already taken tamoxifen for at least 4.5 years.
- Trial name
- NCT00903162
- Testing
- leuprolide, letrozole, zoledronic acid
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Osteoporosis
Tamoxifen to Prevent Bone Loss and Heart Disease in Premenopausal Women Receiving Chemotherapy for Stage I or Stage II Breast Cancer
RATIONALE: Tamoxifen may be able to increase bone density and decrease cholesterol in women who are undergoing chemotherapy for breast cancer.
- Trial name
- NCT00005605
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Northwestern University
Breast Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS)…
- Trial name
- OFSET (NCT05879926)
- Testing
- Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression
- Where
- 1,261 sites in United States, Canada and 6 more
- Volunteers
- 3,960 people
- Sponsor
- NRG Oncology
Breast Cancer
Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
To evaluate the antitumor activity, toxicity, and effectiveness of the combination of goserelin (Zoladex) and anastrozole (Arimidex) in the treatment of premenopausal women with hormone receptor positive metastatic carcinoma of…
- Trial name
- NCT00186121
- Testing
- Anastrozole (Arimidex), Goserelin (Zoladex)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Stanford University
Breast Atypical Hyperplasia, Breast Carcinoma
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing breast cancer.
- Conditions
- Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Trial name
- NCT05941520
- Testing
- Acolbifene Hydrochloride, Biospecimen Collection, Mammography
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)